Abecma denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for abecma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Issue a "Not FDA-Approved" Denial for Abecma

This denial type is frequently a coding or documentation mismatch rather than a reflection of Abecma's actual regulatory status. Abecma (idecabtagene vicleucel) is an FDA-approved CAR-T cell therapy for multiple myeloma. However, insurers sometimes issue this denial when the submitted diagnosis code, indication description, or HCPCS billing code does not clearly map to the specific FDA-approved indication as written. A denial can also occur when a claim references an off-label use, or when clinical documentation fails to specify that the use matches the approved labeling precisely.

## Your Right to Appeal

If the denial rests on a factual error — that is, Abecma is being used within its FDA-approved indication but the claim was miscoded or documentation was incomplete — the appeal should be straightforward to win. Under ACA §2719 external review rights and ERISA §503 full-and-fair review requirements, you are entitled to see the specific basis for the denial and to submit evidence correcting it. External review must generally be requested within four months of the final internal denial. Expedited appeal is available when your health would be seriously jeopardized by delay.

## Building Your Appeal

1. Confirm the approved indication — obtain a copy of the current FDA-approved prescribing information for Abecma directly from the FDA label database (DailyMed) or from the manufacturer. Verify that the patient's diagnosis and treatment history align with the approved indication as written. 2. Audit the claim submission — work with the treating facility's billing team to confirm that the ICD-10 diagnosis codes, the HCPCS procedure code, and any supporting clinical narrative on the claim accurately reflect the approved indication. Correct any discrepancy before resubmitting or filing an appeal. 3. Letter of medical necessity addressing FDA status — the treating hematologist/oncologist should state explicitly in writing that Abecma is being prescribed within its FDA-approved indication, cite the indication language from the prescribing label, and attach the relevant pages of the label as an exhibit. 4. If the use is off-label — if Humana's policy addresses off-label CAR-T use, review it and document support from the applicable NCCN compendium or peer-reviewed evidence per the policy's own standards. Many states and federal guidance require coverage of off-label uses supported by recognized compendia.

## Criteria-Mapping Structure

Create a table with two columns: (1) the exact denial reason language from Humana's denial letter, and (2) the specific evidence rebutting each stated basis — FDA label pages, corrected claim codes, and chart documentation. Attach the FDA prescribing information as Exhibit A.